Co-Authors
This is a "connection" page, showing publications co-authored by Antonio Abbate and Aldo Bonaventura.
Connection Strength
4.310
-
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021 05; 21(5):319-329.
Score: 0.938
-
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Front Immunol. 2020; 11:1625.
Score: 0.890
-
In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure? J Cardiovasc Pharmacol. 2019 07; 74(1):1-3.
Score: 0.830
-
Use of placebo in clinical trials in COVID-19 pandemic times: considerations on pros, cons, challenges and limitations. Minerva Med. 2021 Jul 16.
Score: 0.239
-
The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol. 2021 06; 17(6):601-618.
Score: 0.237
-
Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic. J Clin Transl Sci. 2021; 5(1):e136.
Score: 0.235
-
Inflammasome formation in the lungs of patients with fatal COVID-19. Inflamm Res. 2021 Jan; 70(1):7-10.
Score: 0.227
-
IL-18 and infections: Is there a role for targeted therapies? J Cell Physiol. 2021 03; 236(3):1638-1657.
Score: 0.224
-
Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). J Cardiovasc Pharmacol. 2020 05; 75(5):359-367.
Score: 0.220
-
Drugs to Inhibit the NLRP3 Inflammasome: Not Always On Target. J Cardiovasc Pharmacol. 2019 09; 74(3):225-227.
Score: 0.210
-
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun; 3(6):e410-e418.
Score: 0.058